Original Research
Accepted on 14 Nov 2024
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1480471
Type at least 3 characters
23 articles
Articles
Editorial
Published on 09 May 2024
Editorial: Women in radionuclide therapy: 2023
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1411878
- 590 views
Editorial
Published on 11 Apr 2024
Editorial: Bridging the gap to molecular imaging and theranostics
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1385097
- 988 views
Review
Published on 04 Apr 2024
Immunological effects of radiopharmaceutical therapy
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1331364
- 2,442 views
- 1 citation
Review
Published on 10 Jan 2024
The application of radionuclide therapy for breast cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1323514
- 2,957 views
Original Research
Published on 06 Dec 2023
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1284558
- 1,074 views
Review
Published on 25 Oct 2023
Emerging theragnostic radionuclide applications for hepatocellular carcinoma
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1210982
- 1,731 views
- 1 citation
Review
Published on 04 Aug 2023
Theranostics in breast cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1236565
- 3,497 views
- 3 citations
Case Report
Published on 03 Aug 2023
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1193880
- 919 views
- 1 citation
Review
Published on 27 Jul 2023
Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1224905
- 1,168 views
Review
Published on 25 Jul 2023
Biodosimetry, can it find its way to the nuclear medicine clinic?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1209823
- 2,701 views
- 1 citation
Mini Review
Published on 23 Jun 2023
A brief overview of targeted radionuclide therapy trials in 2022
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1169650
- 4,488 views
- 1 citation
Original Research
Published on 15 May 2023
Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.964478
- 1,581 views
- 1 citation
Original Research
Published on 21 Mar 2023
Insights into handling and delivery of Y-90 radioembolization therapies
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1075782
- 2,881 views
Case Report
Published on 23 Feb 2023
Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1074948
- 1,780 views
- 2 citations
Case Report
Published on 17 Jan 2023
Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.1071022
- 1,249 views
- 1 citation